Diabetes care and e-commerce are explosive industries set to see tremendous growth over the coming decade. DexCom is rolling out its latest product, and a new Medicare ruling should expand its total a
Since early 2022, everyday investors and Wall Street's brightest billionaire money managers have flocked to stocks enacting splits. The sustained competitive advantages offered by three stock-split st
CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.
Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.

The Best Stocks to Invest $500 in Right Now

10:07am, Thursday, 25'th May 2023
Concerns about the economy linger among investors, but some companies could show resilience. DexCom is serving a constant and growing need with its continuous glucose monitoring devices.
Teladoc remains one of the best telehealth prospects despite a rough past 12 months. DexCom is still just scratching the surface of a large opportunity related to continuous glucose monitoring.
The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public o
As more states legalize sports betting, DraftKings stock benefits from a greater pool of potential customers. DexCom's continuous glucose monitoring devices help diabetics keep track of their conditio

3 Stocks on the Verge of Breaking Out

09:55am, Monday, 15'th May 2023
Andrew Rocco combines fundamentals and technicals to bring you 3 top stocks on the verge of breaking out.
Profits are down at S&P 500 companies at large. But a few are putting up monster profit gains that seem to have no bounds.
These five stocks offer investors a variety of options across multiple sectors. The post S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points appeared first on Investor's Business Daily.
Dexcom stock rebounds as glucose monitor maker sees expanding market. The med tech raised revenue guidance in its Q1 earnings report.
Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumor

Is Dexcom a Good Stock to Buy Now?

05:14am, Tuesday, 02'nd May 2023
Dexcom recently reported results from the first quarter of 2023 and reactions were mixed. Wall Street analysts cheered but shares of Dexcom fell a couple of percentage points.
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE